A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
The purpose of this study is to find out whether it is better to receive a new drug, BBI608,
in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as
second line treatment for gastric and gastroesophageal junction cancer after prior first
line platinum and fluoropyrimidine based chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society